StockNews.com Begins Coverage on Trinity Biotech (NASDAQ:TRIB)

Analysts at StockNews.com began coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a research report issued to clients and investors on Saturday. The brokerage set a “sell” rating on the stock.

Trinity Biotech Price Performance

Shares of NASDAQ TRIB opened at $0.69 on Friday. The firm’s 50-day moving average is $0.79 and its two-hundred day moving average is $1.13. The company has a market capitalization of $12.53 million, a PE ratio of -0.31 and a beta of 1.20. Trinity Biotech has a 12-month low of $0.63 and a 12-month high of $3.55.

Institutional Trading of Trinity Biotech

An institutional investor recently raised its position in Trinity Biotech stock. Hunter Associates Investment Management LLC boosted its position in Trinity Biotech plc (NASDAQ:TRIB) by 5.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 378,590 shares of the company’s stock after purchasing an additional 18,780 shares during the quarter. Hunter Associates Investment Management LLC’s holdings in Trinity Biotech were worth $334,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 78.97% of the company’s stock.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.